EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Antibody-mediated rejection in ABO-incompatible kidney transplantation

Kai Castrezana Lopez, Lukas Weidmann iD, Dusan Harmacek, Fabian Roessler iD, Britta George, Seraina von Moos, Kerstin Huebel, Elena Rho iD, Thomas Schachtner iD

Nephrology Dialysis Transplantation · 2026

DOI: 10.1093/ndt/gfaf224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2026. Verfasst von Kai Castrezana Lopez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, ABO Blood-Group System, Blood Group Incompatibility. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: USZ Foundation, Baugarten Foundation, SwissLife Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and hypothesis In ABO-incompatible (ABOi) kidney transplantation, C4d deposition is associated with accommodation rather than rejection. Isoagglutinins targeting blood group antigens A/B are also classified as donor-specific antibodies (DSA). Therefore, the diagnosis of antibody-mediated rejection (AMR) relies primarily on microvascular inflammation (MVI).

Methods

We analyzed 66 ABOi and 251 ABO-compatible (ABOc) kidney transplant recipients (KTRs) concerning anti-human leukocyte antigen (HLA) DSA development. Forty-six protocol biopsies from ABOi KTRs were classified according to Banff 2022. In addition, 25 ABOi protocol biopsies were assessed by the Molecular Microscope Diagnostics System (MMDx) and compared with ABOc biopsies: (i) 35 DSA-negative, C4d-negative cases with MVI <2, (ii) 16 C4d-positive cases with MVI <2, (iii) 35 DSA-positive, C4d-negative cases with MVI = 1 (probable AMR) and (iv) 87 C4d-negative/positive cases with MVI ≥2.

Results

ABOi KTRs showed lower rates of de novo anti-HLA DSA (P = .001) and clinical AMR (P = .018) than ABOc KTRs. Among 25 ABOi protocol biopsies analyzed with MMDx, 56% met AMR criteria due to anti-A/B DSA: 20% active AMR, 20% probable AMR and 16% chronic AMR. However, molecular AMR was confirmed in only 14% by MMDx (P < .001). ABOi and DSA-negative, C4d-negative ABOc biopsies with an MVI below threshold did not differ in molecular rejection, archetype and lesion scores (P > .05) and showed stable graft function. Molecular AMR classifier scores were significantly lower in ABOi and DSA-negative, C4d-negative ABOc cases with MVI below threshold compared with C4d-positive ABOc and ABOc cases with probable AMR (P = .007). Notably, C4d drives molecular AMR activity in ABOc biopsies already at C4d1 levels by immunofluorescence (P = .011) and even in the absence of a histological Banff AMR diagnosis (P = .003).

Conclusion

ABOi transplantation reduces the risk of developing de novo anti-HLA DSA. Banff 2022 criteria may over-diagnose AMR. Biopsy-based transcript diagnostics differentiate anti-HLA- and anti-A/B-mediated alloimmune injury from C4d deposition due to accommodation. Interestingly, C4d deposition drives molecular AMR activity in ABOc biopsies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationGraft RejectionABO Blood-Group SystemBlood Group IncompatibilityIsoantibodiesKidney Failure, ChronicHumansFemaleMaleMiddle AgedAdultGraft SurvivalHLA AntigensComplement C4bPrognosisFollow-Up StudiesRetrospective StudiesGlomerular Filtration RateRisk FactorsPeptide Fragments

Stichwörter der Autor:innen

ABO incompatible kidney transplantationantibody-mediated rejectionbiopsy-based transcript diagnostics

Substanzen

ABO Blood-Group SystemIsoantibodiesHLA AntigensComplement C4bcomplement C4dPeptide Fragments

Autor:innen und Institutionen

  • Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.
  • Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.

ORCID-Profile: Lukas Weidmann, Fabian Roessler, Elena Rho, Thomas Schachtner

Förderung

  • USZ Foundation
  • Baugarten Foundation
  • SwissLife Foundation

Zitieren

APA

Castrezana Lopez, K., Weidmann, L., Harmacek, D., Roessler, F., George, B., von Moos, S., Huebel, K., Rho, E., & Schachtner, T. (2026). Antibody-mediated rejection in ABO-incompatible kidney transplantation. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf224

Vancouver

Castrezana Lopez K, Weidmann L, Harmacek D, Roessler F, George B, von Moos S, et al. Antibody-mediated rejection in ABO-incompatible kidney transplantation. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfaf224

BibTeX
@article{CastrezanaLopez2026,
  author = {Castrezana Lopez, Kai and Weidmann, Lukas and Harmacek, Dusan and Roessler, Fabian and George, Britta and von Moos, Seraina and Huebel, Kerstin and Rho, Elena and Schachtner, Thomas},
  title = {Antibody-mediated rejection in ABO-incompatible kidney transplantation},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfaf224}
}
Kostenlos starten →